EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
Julian PuppeMark OpdamPhilip C SchoutenKatarzyna JóźwiakEsther LipsTesa SeversonMarieke van de VenChiara BrambillascaPeter BouwmanOlaf van TellingenRené BernardsJelle WesselingChristian EichlerFabinshy ThangarajahWolfram MalterGaurav Kumar PandeyLuka OzretićCarlos CaldasMaarten van LohuizenMichael HauptmannKerstin RhiemEric HahnenH Christian ReinhardtReinhard BüttnerPeter MallmannBirgid Schömig-MarkiefkaRita SchmutzlerSabine LinnJos JonkersPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Our findings demonstrate that EZH2 is expressed at significantly higher levels in BRCA1-deficient breast cancers. EZH2 overexpression can identify patients with breast cancer who benefit significantly from intensified DSB-inducing platinum-based chemotherapy independent of BRCA1-like status. EZH2 inhibition improves the antitumor effect of platinum drugs in Brca1-deficient breast tumors in vivo.